CPRISP predicts where RNA-binding proteins interact with circular RNAs by combining transcript, structural and protein features. The Nature Communications paper reports improvements across 37 benchmark datasets, then uses the predictions to investigate pathways linked to neurodegenerative disease and prioritize compounds for laboratory follow-up. These are research leads rather than evidence of treatment efficacy.[1]
The system, called CPRISP, combines circular-RNA sequence composition, physicochemical properties, secondary structure, pretrained representations and protein-specific features. Across 37 benchmark datasets, the authors report improved interaction-site prediction and generalization across cell lines. Model interpretation recovered conserved single-stranded sequence patterns, providing a biological check on what the network had learned.[1]
From molecular prediction to therapeutic hypothesis
| Stage | What CPRISP contributes | Evidence boundary |
|---|---|---|
| Binding-site prediction | Scores where a protein is likely to interact with a circular RNA | Computational prediction across benchmark datasetsSource 1 |
| Interpretation | Highlights conserved single-stranded sequence patterns | Supports plausibility but does not prove every predicted interactionSource 1 |
| Disease analysis | Finds recurrent pathways involving nucleocytoplasmic transport, lysosomal signalling and GTPase activity | Association and network prioritizationSource 1 |
| Compound prioritization | Ranks candidates for experimental follow-up | No therapeutic efficacy establishedSource 1 |
Circular RNAs add a structural problem
Circular RNAs are formed when an RNA molecule closes into a loop rather than retaining the usual free ends. Their interactions with RNA-binding proteins can influence stability, localization and gene regulation. Predicting those interactions is difficult because the binding signal can depend on both local sequence and higher-order structure, while the relevant protein contributes its own biochemical preferences.
Earlier approaches often emphasized transcript features and made less use of protein-specific information or structural context. CPRISP integrates both sides of the interaction. That design is important for generalization: a motif associated with one protein should not automatically be treated as evidence for another, and the same RNA sequence may present different accessible regions depending on its structure.[1]
Interpretability is a biological test, not a guarantee
The authors report that interpretation methods recovered conserved single-stranded sequence patterns. This is useful because many RNA-binding interactions depend on accessible, unpaired regions. When a model’s important features align with known biological structure, the prediction becomes easier to investigate. It remains possible for a model to combine a meaningful motif with dataset-specific shortcuts, so interpretation must be tested through perturbation and binding assays.[1]
The disease result is a map of experiments
For proteins linked to the three neurodegenerative diseases, the analysis repeatedly surfaced pathways involving nucleocytoplasmic transport, lysosomal signalling and GTPase activity. These processes have plausible connections to protein handling and cellular maintenance. The recurrence can help researchers choose which predicted RNA-protein interactions to validate first and which downstream measurements to collect.[1]
The compound shortlist is a proposal for experiments. Computational prioritization does not establish that a molecule reaches the relevant tissue, alters the predicted interaction or benefits patients at a safe dose. The authors explicitly frame the candidates as leads for follow-up.[1]
The useful output is a narrower set of binding sites and disease-linked pathways to investigate. Experiments can then test whether the predicted interaction occurs and whether changing it affects the proposed biology. That separates the model’s screening role from a therapeutic claim.[1]
Sources & further reading
- CPRISP: an interpretable deep learning framework predicting circRNA-RBP interactions and guiding therapeutic discovery in neurodegeneration Nature Communications · 28 Oct 2026 · Accessed 30 Oct 2026